Sign inJoin waitlistJoin the waitlist

Roger S. Lo

Dermatology · The Regents of the University of California

Credentials: · · ·

History

UCLA School of Medicine
Until 2006
St. Vincent's Hospital and Medical Center of NY
Until 2003
Weill Cornell Medical College
2002

Research

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
New England Journal of Medicine · 2016 · 2,646 citations
TGFbeta signaling in growth control, cancer, and heritable disorders
Review · Cell · 2000 · Last of 3 authors · 2,039 citations
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Nature · 2010 · Last of 16 authors · 1,769 citations

Antoni Ribas
43 papers
Jeffrey Sosman
16 papers
Douglas Johnson
11 papers
Igor Puzanov
11 papers
Bartosz Chmielowski
9 papers
Thomas Gajewski
8 papers
CN
Charles Ng
7 papers
Jennifer Wargo
7 papers
Keith Flaherty
7 papers
Marcus Bosenberg
6 papers
Philip Scumpia
6 papers
Marc Ernstoff
5 papers

Grants

Preventing MAPK Inhibitor Resistance in Melanoma by Targeting Genomic Instability and Immune Resistance
National Cancer Institute · R01
Contact PI · $5.4M · University of California Los Angeles
2013–2029
Melanoma Resistance Evolution Atlas (MREA) for Identifying Combinatorial Targets to Prevent and Reverse MAPKi Resistance
National Cancer Institute · R01
Contact PI · $2M · University of California Los Angeles
2024–2029
Spatiotemporal Tumor Analytics for Guiding Sequential Targeted-Inhibitor: Immunotherapy Combinations (ST-Analytics)
National Cancer Institute · U54
Project lead · $1.5M · Institute for Systems Biology
2022–2027
Combination Therapies to Defeat Melanoma Resistance
National Cancer Institute · P01
Project lead · $2.5M · University of California Los Angeles
2020–2025

Clinical trials

Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma
Principal investigator · Terminated · Phase 2
Jonsson Comprehensive Cancer Center
2020–2024